SCHEMBL8429157

SCHEMBL8429157

O=C(O)C1CCC(C2CCCC(C3CCC(C(=O)O)CC3)C2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 2/20 0.41
PLG P00747 1/20 0.41
PLAT P00750 1/20 0.41
TSHR P16473 3/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
GABRA4 P48169 1/20 0.41
GABRE P78334 1/20 0.41
PMP22 Q01453 1/20 0.41
GABRA6 Q16445 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16769013 0.93 LMNA (0.46) MEN1KMT2ALMNAPLGPLAT
SCHEMBL16604542 0.91 ACE (0.41) MEN1KMT2ALMNAPLGPLAT
SCHEMBL2494999 0.87 LMNA (0.46) MEN1KMT2ALMNAPLGPLAT
SCHEMBL28931985 0.87 LMNA (0.46) MEN1KMT2ALMNAPLGPLAT
SCHEMBL16769014 0.87 LMNA (0.46) MEN1KMT2ALMNAPLGPLAT
SCHEMBL2460791 0.86 ACE (0.41) MEN1KMT2ALMNAPLGPLAT
SCHEMBL11216737 0.86 ACE (0.41) MEN1KMT2ALMNAPLGPLAT
SCHEMBL31453008 0.86 ACE (0.41) MEN1KMT2ALMNAPLGPLAT
SCHEMBL6225010 0.85 LMNA (0.44) MEN1KMT2ALMNAPLGPLAT
SCHEMBL11070544 0.85 LMNA (0.44) MEN1KMT2ALMNAPLGPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5756634-A Liquid one component PU stoving enamels HUELS AKTIENGESELLSCHAFT (DE) 1998-05-26 US claimed
US-9795586-B2 HNF4-α antagonist and use thereof NATIONAL CANCER CENTER (KR) 2017-10-24 US disclosed
US-9795586-B2 HNF4-α antagonist and use thereof NATIONAL CANCER CENTER (KR) 2017-10-24 US disclosed
US-20170189371-A1 HNF4-alpha ANTAGONIST AND USE THEREOF NATIONAL CANCER CENTER (KR) 2017-07-06 US disclosed
US-20170189371-A1 HNF4-alpha ANTAGONIST AND USE THEREOF NATIONAL CANCER CENTER (KR) 2017-07-06 US disclosed
US-20160193238-A1 HNF4-alpha ANTAGONIST AND USE THEREOF NATIONAL CANCER CENTER (KR) 2016-07-07 US disclosed
US-20160193238-A1 HNF4-alpha ANTAGONIST AND USE THEREOF NATIONAL CANCER CENTER (KR) 2016-07-07 US disclosed
EP-0761705-B1 Liquid one-component polyurethane storing lacquers DEGUSSA (DE) 1999-11-24 EP disclosed
US-5756634-A Liquid one component PU stoving enamels HUELS AKTIENGESELLSCHAFT (DE) 1998-05-26 US disclosed
EP-0761705-A1 Liquid one-component polyurethane storing lacquers HÜLS AKTIENGESELLSCHAFT (DE) 1997-03-12 EP disclosed
US-4430474-A POLYESTERURETHANES CONTAINING URETIDIONE AND ISOPHORONE GROUPS; STORAGE STABILITY; COATINGS CHEMISCHE WERKE HUELS AG (DE) 1984-02-07 US disclosed
EP-0001468-B1 POWDERED COATING PRODUCTS, PROCESS FOR THEIR PREPARATION AND THEIR USE CHEMISCHE WERKE HÜLS AG (DE) 1982-05-12 EP disclosed
EP-0001467-B1 STOVING LACQUERS HAVING AN EXTENDED POT LIFE ON THE BASIS OF POLYISOCYANATE MASKED WITH IMIDAZOLINES CHEMISCHE WERKE HÜLS AG (DE) 1981-10-21 EP disclosed
US-4255551-A EXTRUDING WITH A SOLID HYDROXYL GROUP-CONTAINING POLYESTER, COOLING, MILLING, SCREENING; STORAGE STABILITY CHEMISCHE WERKE HULS AG (DE) 1981-03-10 US disclosed
US-4242248-A WEATHER RESISTANT COIL COATING CHEMISCHE WERKE HULS AG (DE) 1980-12-30 US disclosed
US-4151152-A POLYESTERURETHANES, SHELF LIFE VEBA-CHEMIE AKTIENGESELLSCHAFT (DE) 1979-04-24 US disclosed
EP-0001468-A1 Powdered coating products, process for their preparation and their use CHEMISCHE WERKE HÜLS AG (DE) 1979-04-18 EP disclosed
EP-0001467-A1 Stoving lacquers having an extended pot life on the basis of polyisocyanate masked with imidazolines CHEMISCHE WERKE HÜLS AG (DE) 1979-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189371-A1 HNF4-alpha ANTAGONIST AND USE THEREOF HNF4A, TCF4, WNT3A MEN1 4787/4885KMT2A 1796/4885LMNA 4194/4885
US-20160193238-A1 HNF4-alpha ANTAGONIST AND USE THEREOF HNF4A, TCF4, WNT3A MEN1 4787/4885KMT2A 1796/4885LMNA 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.